How would you manage adjuvant therapy in a BRCA1-mutated woman with ER+, Her2 negative breast cancer with residual disease at surgery after neoadjuvant therapy with a taxane-based regimen?

Topics: Breast Cancer • Medical Oncology

Could carboplatin be considered here? Or any evidence for a PARP inhibitor?

Answer from: Medical Oncologist at Academic Institution

There are several factors to consider in this case. One is whether the patient has received optimum chemotherapy. If there is only minimum residual disease at surgery, I would not recommend additional chemotherapy in the adjuvant setting. On the other hand, if there was signific...

Comments

Medical Oncologist at Uniformed Services University of the Health Sciences (USUHS)
Would you offer adjuvant capecitabine if patient h...

Medical Oncologist at Clinical Instructor
To call readers attention, we do have similar ques...

Related Questions